A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia

NCT03771664 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

87

Enrollment

INDUSTRY

Sponsor class

Stopped internal company decision

Conditions

Major Depressive Disorder
Insomnia

Interventions

DRUG: SAGE-217
DRUG: Placebo

Sponsor

Biogen